EOLS

+ Watchlist + Portfolio

Evolus, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.69
52-Week Range: $3.86 – $9.31
Market Cap: $471.60M
P/E (TTM): —
EPS (TTM): -0.53
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -5.68%
Gross Margin: 66.40%
Operating Margin: -5.17%
Profit Margin: -10.85%
Current Ratio: 1.70
Debt/Equity: —
Total Debt: $164.80M
Free Cash Flow: $-1.82M
Revenue Growth: 21.20%
Earnings Growth: —
Enterprise Value: $591.23M

EOLS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$148.62M	$202.09M	$266.27M	$297.18M
Cost of Revenue	$58.84M	$64.51M	$83.97M	$100.07M
Gross Profit	$89.77M	$137.57M	$182.30M	$197.11M
Research & Development	$6.74M	$15.43M	$9.17M	$9.58M
Selling, General & Admin	$141.84M	$164.94M	$198.03M	$220.79M
Operating Expenses	$149.35M	$182.55M	$209.54M	$234.71M
Operating Income	-$59.58M	-$44.98M	-$27.23M	-$37.60M
EBITDA	-$60.72M	-$41.81M	-$25.00M	-$22.53M
Pretax Income	-$74.32M	-$61.51M	-$49.76M	-$50.96M
Income Tax	$95.00K	$176.00K	$664.00K	$677.00K
Net Income	-$74.41M	-$61.69M	-$50.42M	-$51.64M
Diluted EPS	-1.33	-1.08	-0.81	-0.80
Diluted Shares	56.06M	56.92M	62.25M	64.47M

EOLS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$53.92M	$62.84M	$86.95M	$53.83M
Receivables	$22.45M	$30.53M	$47.68M	$54.70M
Inventory	$18.85M	$11.00M	$12.16M	$26.96M
Current Assets	$100.80M	$112.42M	$151.34M	$142.92M
Total Assets	$177.98M	$189.00M	$232.57M	$225.87M
Current Liabilities	$46.51M	$48.29M	$62.96M	$75.31M
Long-Term Debt	$71.88M	$120.36M	$121.51M	$146.10M
Total Debt	$74.42M	$126.55M	$129.98M	$155.00M
Total Liabilities	$159.48M	$209.69M	$227.05M	$248.97M
Retained Earnings	-$497.29M	-$558.98M	-$609.40M	-$661.04M
Shareholders' Equity	$18.50M	-$20.69M	$5.52M	-$23.11M
Working Capital	$54.29M	$64.13M	$88.38M	$67.61M
Net Debt	$17.96M	$57.52M	$34.55M	$92.27M

EOLS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$84.91M	-$34.01M	-$18.00M	-$42.27M
Capital Expenditure	-$2.94M	-$1.63M	-$4.82M	-$8.45M
Free Cash Flow	-$87.85M	-$35.63M	-$22.82M	-$50.72M
Depreciation & Amortisation	$4.50M	$5.87M	$6.02M	$8.74M
Stock-Based Compensation	$10.83M	$16.46M	$22.25M	$20.70M
Investing Cash Flow	-$2.94M	-$1.63M	-$4.82M	-$8.45M
Financing Cash Flow	-$4.15M	$44.64M	$47.41M	$17.34M
Net Change in Cash	-$92.00M	$9.01M	$24.59M	-$33.38M

EOLS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$68.52M	$69.39M	$68.97M	$90.30M	$73.14M	$84.08M
Cost of Revenue	$21.87M	$24.07M	$23.13M	$31.01M	$24.24M	$26.90M
Gross Profit	$46.66M	$45.32M	$45.84M	$59.29M	$48.90M	$57.18M
Research & Development	$2.21M	$1.84M	$2.05M	$3.48M	$2.24M	$1.89M
Selling, General & Admin	$56.64M	$56.67M	$52.82M	$54.66M	$51.98M	$57.05M
Operating Expenses	$59.68M	$59.44M	$56.01M	$59.58M	$55.76M	$60.47M
Operating Income	-$13.02M	-$14.12M	-$10.16M	-$291.00K	-$6.86M	-$3.29M
EBITDA	-$12.58M	-$7.83M	-$9.20M	$7.08M	-$3.75M	-$1.34M
Pretax Income	-$18.82M	-$17.09M	-$15.57M	$515.00K	-$10.42M	-$8.21M
Income Tax	$72.00K	$53.00K	$167.00K	$385.00K	$256.00K	-$154.00K
Net Income	-$18.89M	-$17.14M	-$15.74M	$130.00K	-$10.67M	-$8.05M
Diluted EPS	-0.30	-0.27	-0.24	0.00	-0.16	-0.12
Diluted Shares	63.70M	64.54M	64.73M	65.35M	65.19M	65.93M

EOLS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$67.89M	$61.74M	$43.52M	$53.83M	$49.79M	$45.17M
Receivables	$47.45M	$47.71M	$50.44M	$54.70M	$52.22M	$62.38M
Inventory	$10.03M	$26.46M	$32.87M	$26.96M	$24.80M	$40.90M
Current Assets	$131.72M	$144.97M	$134.89M	$142.92M	$138.92M	$167.54M
Total Assets	$213.36M	$228.80M	$219.00M	$225.87M	$220.65M	$248.02M
Current Liabilities	$56.23M	$63.75M	$66.71M	$75.31M	$68.02M	$98.73M
Long-Term Debt	$121.81M	$145.47M	$145.78M	$146.10M	$156.41M	$156.74M
Total Debt	$130.20M	$154.91M	$154.89M	$155.00M	$164.90M	$164.80M
Total Liabilities	$219.97M	$247.46M	$247.76M	$248.97M	$249.43M	$278.93M
Retained Earnings	-$628.29M	-$645.43M	-$661.17M	-$661.04M	-$671.71M	-$679.77M
Shareholders' Equity	-$6.60M	-$18.65M	-$28.76M	-$23.11M	-$28.78M	-$30.90M
Working Capital	$75.48M	$81.22M	$68.18M	$67.61M	$70.90M	$68.81M
Net Debt	$53.91M	$83.74M	$102.26M	$92.27M	$106.62M	$111.57M

EOLS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$15.63M	-$24.79M	-$14.67M	$12.83M	-$9.95M	-$3.59M
Capital Expenditure	-$1.86M	-$2.27M	-$2.16M	-$2.17M	-$1.69M	-$500.00K
Free Cash Flow	-$17.49M	-$27.06M	-$16.83M	$10.66M	-$11.64M	-$4.09M
Depreciation & Amortisation	$1.82M	$2.05M	$2.28M	$2.59M	$2.69M	$2.69M
Stock-Based Compensation	$5.93M	$4.49M	$5.13M	$5.15M	$5.12M	$5.62M
Investing Cash Flow	-$1.86M	-$2.27M	-$2.16M	-$2.17M	-$1.69M	-$500.00K
Financing Cash Flow	-$1.63M	$20.66M	-$1.77M	$77.00K	$7.62M	-$365.00K
Net Change in Cash	-$19.12M	-$6.39M	-$18.60M	$10.74M	-$4.02M	-$4.45M

Market Snapshot

About

Evolus is a performance beauty company focused on delivering innovative aesthetic products. The company's flagship product is Jeuveau, a proprietary neurotoxin used for the temporary improvement of moderate to severe glabellar lines. Evolus markets its products primarily to medical aesthetic practitioners in the United States. The company competes in the growing medical aesthetics market with a focus on building customer loyalty and expanding its product portfolio.